Tag Archives: commercialization

The strategic plan that has guided Arizona’s fast-growing bioscience sector for nearly 12 years is gearing up for a new decade.

“Arizona’s Bioscience Roadmap: 2014-2025” will be unveiled starting April 8 at events in Phoenix, Tucson, and Flagstaff, the state’s three metropolitan areas that feature growing bioscience hubs. The plan includes updated strategies that can strengthen and diversify Arizona’s economy while providing Arizonans access to the latest health care innovations.

“The updated Bioscience Roadmap builds on the successes of its first decade and adds contemporary strategies to take Arizona’s bioscience base to the next level,” said Jack Jewett, President & CEO of the Flinn Foundation, which commissioned the update and the original Bioscience Roadmap in 2002. “Arizona is now known as a top emerging bioscience state, but we have far to go to reach our full potential.”

The updated Roadmap will continue to focus on developing Arizona’s biomedical research infrastructure but will emphasize turning this research into new therapies, products, diagnostics, jobs, firms, and other benefits to Arizona. Commercialization, entrepreneurship, creating a critical mass of bioscience firms, and the development of talent are prime themes.

The Roadmap’s overarching vision is for Arizona—a young but rapidly growing state in the biosciences—to become a global competitor and national leader in select areas of the biosciences by 2025.

Over the first decade, Arizona built major research facilities at its universities, formed new private research institutes, attracted top talent, created high-tech business incubators, and greatly expanded statewide STEM (science, technology, education, math) education programs. The number of Arizona bioscience industry jobs grew by 45 percent, nearly four times greater than the nation.

“Arizona has many bioscience strengths and opportunities, but a substantial increase in private and public investment will be needed over the next decade to realize the Roadmap’s goals,” said Walter Plosila, senior advisor to the Battelle Technology Partnership Practice, the Columbus, Ohio-based nonprofit research and development organization that authored the original Roadmap and its update.

Plosila noted that Arizona’s greatest needs are access to risk capital by startup and emerging bioscience firms, building a stronger bioscience entrepreneurship culture, and an expansion of the research infrastructure combined with commercialization at the state’s universities.

The new Roadmap plan features five goals, 17 strategies, and 77 proposed actions. The actions are meant to evolve as needs change over the course of the decade. The plan was developed by Battelle following research, interviews, and focus groups with more than 150 local and national bioscience leaders, including extensive input from Arizona’s Bioscience Roadmap Steering Committee, a body of more than 100 statewide leaders in science, business, academia, and government.

“An emphasis on the full spectrum of the biosciences—from research to hospitals to bio-agriculture—and a renewed focus on resources, collaboration, and long-term patience is needed for Arizona to continue its ascent in the biosciences,” said Martin Shultz, Senior Policy Director for Brownstein Hyatt Farber Schreck, who chairs the Roadmap Steering Committee. “The impact can be profound—the biosciences are a multibillion-dollar industry for Arizona.”

There are six industry segments that comprise the biosciences in Arizona: agricultural feedstock and chemicals; drugs, pharmaceuticals, and diagnostics; medical devices and equipment; research, testing, and medical labs; bioscience-related distribution; and hospitals. A new economic-impact analysis by Battelle estimates the total revenue generated annually by Arizona’s bioscience industry—not counting hospitals—to be $14 billion. With hospitals included, the figure exceeds $36 billion.

Based on the latest industry data (2012), Arizona currently has 106,846 bioscience jobs spread across 1,382 establishments and an annual average wage of $62,775—39 percent higher than the private-sector average. These numbers do not include academic research jobs at the state universities or private research institutes.

Hospitals account for the majority of the state’s bioscience jobs. With hospitals removed from the equation, the other segments combine for 23,545 jobs, 1,266 establishments, and average annual wages of $85,571. Growth in the non-hospital segments accelerated dramatically over the last few years.

The bioscience-related distribution subsector is a new addition to Arizona’s bioscience definition, following the lead of the Biotechnology Industry Organization, the nation’s bioscience trade association. Companies in this subsector coordinate the delivery of bioscience-related products through processes such as cold storage and product monitoring, and new technologies such as automated pharmaceutical distribution systems. This change also called for several smaller industries to be dropped from Arizona’s definition.

The Roadmap also presents updated data on Arizona’s performance in generating grants from the National Institutes of Health, academic research expenditures, venture capital, and tech-transfer measures involving the state universities. These metrics plus industry measures will be tracked throughout the decade by Battelle and reported by the Flinn Foundation.

The Roadmap also includes analyses of Arizona’s bioscience sector that were critical in developing the strategies and actions, such as an assessment of Arizona’s bioscience strengths, weaknesses, opportunities, and challenges. It identified Arizona’s core competencies as cancer research, neurosciences, bioengineering, agricultural biotechnology, imaging sciences, precision medicine, diagnostics, health information technologies, and health economics.

The Flinn Foundation is a privately endowed, philanthropic grantmaking organization established in 1965 by Dr. Robert S. and Irene P. Flinn to improve the quality of life in Arizona to benefit future generations. The Phoenix-based foundation supports the advancement of the biosciences in Arizona, as well as a merit-based college scholarship program, arts and culture, and the Arizona Center for Civic Leadership. “Arizona’s Bioscience Roadmap: 2014-2025” is available for download at www.flinn.org.

In the story, several leading figures in the sustainability movement sheepishly admit that they, too, sometimes take the easy way out.

Disposable diapers are one example. Several of the individuals interviewed admitted to using them on their children. Despite their best efforts to act in a sustainable manner, often this is easier said than done, and there is no better example out there than babies and their diaper needs.

From having a pool, to owning two homes, the list of green “offenses” goes on. But the message remained the same: no one is perfect in the quest to lead a sustainable lifestyle. What matters most is that the good outweigh the bad. So you use diapers, no problem, but then you’ve got to minimize your impact in other ways and so forth.

In this day and age, it’d be difficult to lead a life that wouldn’t in some shape, way or form harm the environment. There’s no reason to feel guilty. There is a difference between wastefulness and necessity. Making smart choices in places that you can (i.e. recycling, limiting water use, etc) will hopefully make the kind of impact that will make Mother Earth happy with us for years to come.

Dr. Jeffrey M. TrentPresident and Research DirectorTGen

Since it was founded in 2002, the Translational Genomics Research Institute (TGen) has been helping people with neurological disorders and such diseases as cancer and diabetes through business spin-offs and commercialization of its research. Today, TGen’s president and scientific director, Dr. Jeffrey M. Trent, believes this Phoenix nonprofit has built an “underlying bioscience engine” in Arizona.

In fact, with TGen helping to attract and retain a knowledge-based work force, Arizona’s bioscience-research sector has held its own during the recession and even expanded. “As far as jobs are concerned, bioscience is still an area that shows growth in Arizona,” Trent says. That doesn’t mean the recession did not affect the bioscience sector as a whole.

“The area that has fallen the furthest is venture capital to seed new company formation,” Trent says. “There is no question Arizona has been behind the curve in venture capital for biomedical science.”

Last year, TGen announced the formation of its 10th business, but Trent says the organization must “look around the world for funding for these companies.” This is a national problem, he adds, but he is optimistic it will improve this year. Philanthropic donations for bioscience research also slowed during the economic downturn, but Trent already sees a return of that type of funding and is hopeful it will continue to gather momentum this year. Still, TGen has managed to prosper.

“In less than three years, we doubled our economic impact, doubled employment and increased commercial activities 375 percent,” Trent says. “The biomedical sector and nonprofits are being hit as hard as anyone (by the recession), but we were able to not only maintain, but also to grow the last two or three years.”

In an independent analysis, Tripp Umbach, a Pittsburgh research firm, concluded that TGen generates an annual economic impact of $77.4 million, including spin-off businesses and commercialization. TGen’s economic clout is expected to reach $321.3 million annually by 2025, according to Tripp Umbach. Again, including business formation and commercialization in its calculations, Tripp Umbach reported that TGen produced $5.7 million in state taxes, created 461 full-time jobs and generated $14.07 for every dollar invested by the state in 2008.

In addition to federal funding and donations, and grants from businesses, foundations and individuals, TGen receives $5.5 million a year from state tobacco taxes. In 2025, the state’s return on investment is expected to reach $58.42 per dollar invested, tax revenues are estimated to climb to $27.4 million, and TGen is expected to generate more than 4,000 jobs when business and commercialization activities are factored in.

TGen reached several milestones last year, but from Trent’s point of view, the standout was its affiliation with the Van Andel Research Institute, a global organization headquartered in Grand Rapids, Mich.

“This affiliation brings a remarkably complementary scientific skill set under one roof,” Trent says. “Van Andel is basically a discovery engine and TGen gets to capture that and move it to a new test or treatment for patients. We are constantly renewing information that we can pull toward the patient.”